DGRW vs XBI
WisdomTree US Quality Dividend Growth Fund vs SPDR S&P Biotech ETF
- • DGRW has the lower expense ratio at 0.28% vs 0.35% for XBI.
- • DGRW pays a higher dividend yield (1.27%).
Side-by-side metrics
| Metric | DGRW | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.28% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.27% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $16.60B | $10.73B |
YTD return | 7.95% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.82 | 1.10 |
P/E ratio | 25.69 | — |
Last price | $96.39 | $164.01 |
Inception | — | — |
Issuer | WisdomTree | State Street |
DGRW top holdings
| NVDA | NVIDIA Corp | 7.95% |
| MSFT | Microsoft Corp | 5.75% |
| AAPL | Apple Inc | 3.87% |
| META | Meta Platforms Inc Class A | 2.97% |
| UNH | UnitedHealth Group Inc | 2.92% |
| KO | Coca-Cola Co | 2.88% |
| HD | The Home Depot Inc | 2.81% |
| JNJ | Johnson & Johnson | 2.34% |
| AVGO | Broadcom Inc | 2.34% |
| ORCL | Oracle Corp | 2.34% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About DGRW
DGRW (WisdomTree US Quality Dividend Growth Fund) is Dividend-paying US large caps with quality and growth screens. Managed by WisdomTree, the fund carries $16.6B in assets under management, an expense ratio of 0.28%, a dividend yield of 1.27%. Its largest holding is NVIDIA Corp (NVDA), which represents 7.9% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 8.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.